Arcturus JV mRNA manufacturing partner, ARCALIS, awarded $115M in Japan grants

Arcturus Therapeutics Holdings announced that ARCALIS , its manufacturing joint venture in Japan to support the production of mRNA vaccines and therapeutics, has been awarded $115M in two separate grants from the Japanese government. The grants will be used to fund the construction of a factory and the purchase of capital equipment to support current Good Manufacturing Practice cGMP production of mRNA drug substance and mRNA drug product operations. Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115M in Grants from the Japanese Government .ARCALIS is a joint venture between Axcelead and Arcturus, wherein Arcturus holds a 49% equity position that is subject to dilution. The factory, located in Minamisoma City, Japan, is designed to provide cGMP integrated vaccine manufacturing, from mRNA drug substance to bulk nanoparticle-formulated drug product.